The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with the $200 million upsized follow-on offering of 11,108,055 shares of common stock of MBX Biosciences, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “MBX.”

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. The company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Arisa Akashi Sin and associates Jenny (Jingjing) Li and Sijia (Scarlett) Huang. Partner David R. Bauer and associate Jordan Khorshad provided intellectual property advice. Counsel Yixuan Long and associate David J. Beer provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post